Peer-reviewed veterinary case report
A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model.
- Journal:
- Journal of pharmacological sciences
- Year:
- 2025
- Authors:
- Neyama, Hiroyuki et al.
- Affiliation:
- Nagasaki University Graduate School of Biomedical Sciences · Japan
Abstract
Lysophosphatidic acid receptor 1 (LPA) plays a pivotal role in the pathophysiology of various diseases, especially chronic pain. In this study, we assessed the biochemical properties of Compound A, a novel LPAantagonist and its beneficial effects in the fibromyalgia (FM)-like pain model. Compound A was found to be a high-affinity and selective LPAantagonist and have high brain penetrability. Repeated oral administrations of Compound A reversed the hyperalgesia as late as 9 days after the treatments, suggesting this compound has a curative effect in the FM model.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/40288824/